Injection of Lymphocytes From Haplo-identical Donor Following Chemotherapy in Patients With High-risk Acute Myeloblastic Leukemia Not Eligible for an Allogeneic Hematopoietic Stem Cell Transplantation
- Conditions
- Acute Myeloid Leukemia (AML)
- First Posted Date
- 2021-05-13
- Last Posted Date
- 2022-05-11
- Lead Sponsor
- Nantes University Hospital
- Target Recruit Count
- 12
- Registration Number
- NCT04886206
- Locations
- 🇫🇷
CHU de Nantes, Nantes, France
A Modified Dose of Rabbit Anti-thymocyte Globulin (rATG) in Children and Adults Receiving Treatment to Help Prepare Their Bodies for a Bone Marrow Transplant
- Conditions
- Acute Myeloid Leukemia (AML)Acute Lymphoid Leukemia (ALL)Myelodysplastic Syndromes (MDS)
- Interventions
- Other: Personalized rATG (P-rATG)Radiation: Hyper fractionated total body irradiationDrug: GCSF
- First Posted Date
- 2021-05-04
- Last Posted Date
- 2025-09-04
- Lead Sponsor
- Memorial Sloan Kettering Cancer Center
- Target Recruit Count
- 59
- Registration Number
- NCT04872595
- Locations
- 🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States
Study of Oral Venetoclax Tablets to Evaluate Adverse Events and Change in Disease Activity in Participants Above 19 Years of Age With Acute Myeloid Leukemia (AML)
- Conditions
- Acute Myeloid Leukemia (AML)
- First Posted Date
- 2021-04-01
- Last Posted Date
- 2025-07-16
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 600
- Registration Number
- NCT04826523
- Locations
- 🇰🇷
Pusan National University Hospital /ID# 239010, Busan, Busan Gwang Yeogsi, Korea, Republic of
🇰🇷Kosin University Gospel Hospital /ID# 257399, Busan, Busan Gwang Yeogsi, Korea, Republic of
🇰🇷Kyungpook National University Hospital /ID# 257398, Daegu, Daegu Gwang Yeogsi, Korea, Republic of
A Clinical Trial to Evaluate Clifutinib in Patients With Relapsed or Refractory Acute Myeloid Leukemia(AML)
- First Posted Date
- 2021-04-01
- Last Posted Date
- 2022-08-12
- Lead Sponsor
- Sunshine Lake Pharma Co., Ltd.
- Target Recruit Count
- 80
- Registration Number
- NCT04827069
- Locations
- 🇨🇳
the First Affiliated Hospital,College of Medicine,Zhejiang University, Hanzhou, China
GEN3014 Trial in Relapsed or Refractory Hematologic Malignancies
- Conditions
- Relapsed or Refractory Multiple Myeloma (RRMM)Diffuse Large B Cell Lymphoma (DLBCL)Acute Myeloid Leukemia (AML)
- Interventions
- First Posted Date
- 2021-04-01
- Last Posted Date
- 2025-09-03
- Lead Sponsor
- Genmab
- Target Recruit Count
- 130
- Registration Number
- NCT04824794
- Locations
- 🇺🇸
John Theurer Cancer Center, Hackensack, New Jersey, United States
🇺🇸University Hospitals Cleveland Medical Center, Cleveland, Ohio, United States
🇺🇸Medical college of Wisconsin, Milwaukee, Wisconsin, United States
Study of Oral Venetoclax Tablets to Evaluate Adverse Events and Change in Disease Activity in Participants of Any Age With Acute Myeloid Leukemia
- Conditions
- Acute Myeloid Leukemia (AML)
- First Posted Date
- 2021-03-24
- Last Posted Date
- 2025-04-27
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 424
- Registration Number
- NCT04813263
- Locations
- 🇯🇵
Anjou Kousei Hospital /ID# 244213, Anjo-shi, Aichi, Japan
🇯🇵Nagoya City University Hospital /ID# 256177, Nagoya shi, Aichi, Japan
🇯🇵Nagoya City West Medical Center /ID# 250844, Nagoya-shi, Aichi, Japan
Prospective Non-interventional Study of Adult Patients With Acute Myeloid Leukemia (AML)
- Conditions
- Acute Myeloid Leukemia (AML)
- First Posted Date
- 2021-03-02
- Last Posted Date
- 2024-01-31
- Lead Sponsor
- Acute Leukemia French Association
- Target Recruit Count
- 2500
- Registration Number
- NCT04777916
- Locations
- 🇫🇷
Chu Amiens, Amiens, France
🇫🇷Centre Hospitalier Victor Dupouy, Argenteuil, France
🇫🇷AP-HP-GHU - Hôpital AVICENNE, Bobigny, France
A Study of SKLB1028 Versus Salvage Chemotherapy in Patients With Relapsed or Refractory (R/R) AML With FLT3-Mutated
- Conditions
- Acute Myeloid Leukemia (AML)
- Interventions
- Drug: Salvage Chemotherapy
- First Posted Date
- 2021-01-20
- Last Posted Date
- 2021-11-02
- Lead Sponsor
- CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
- Target Recruit Count
- 315
- Registration Number
- NCT04716114
- Locations
- 🇨🇳
West China hospital of Sichuan University, Chengdu, Sichuan, China
VOB560-MIK665 Combination First in Human Trial in Patients With Hematological Malignancies (Relapsed/Refractory Non-Hodgkin Lymphoma, Relapsed/Refractory Acute Myeloid Leukemia, or Relapsed/Refractory Multiple Myeloma)
- Conditions
- Non-Hodgkin Lymphoma (NHL)Acute Myeloid Leukemia (AML)Multiple Myeloma (MM)
- Interventions
- First Posted Date
- 2021-01-08
- Last Posted Date
- 2025-06-25
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 37
- Registration Number
- NCT04702425
- Locations
- 🇺🇸
Uni of TX MD Anderson Cancer Cntr UT MD Anderson Cancer Ctr, Houston, Texas, United States
🇪🇸Novartis Investigative Site, Santander, Cantabria, Spain
A Study to Assess the Safety of Xospata in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) With FMS-Like Tyrosine Kinase 3 (FLT3) Mutation
- Conditions
- Acute Myeloid Leukemia With FMS-like Tyrosine Kinase (FLT3) Mutation
- Interventions
- First Posted Date
- 2020-12-31
- Last Posted Date
- 2025-05-31
- Lead Sponsor
- Astellas Pharma Korea, Inc.
- Target Recruit Count
- 33
- Registration Number
- NCT04691648
- Locations
- 🇰🇷
Site KR82013, Wonju-si, Gangwon-do, Korea, Republic of
🇰🇷Site KR82006, Goyang-si, Gyeonggi-do, Korea, Republic of
🇰🇷Site KR82003, Jeollanam-do, Hwasun-gun, Korea, Republic of